Palisade Bio (Palisade Bio) Float Percentage Of Total Shares Outstanding : 98.55% (As of Jun. 18, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Palisade Bio's float shares is 0.93 Mil. Palisade Bio's total shares outstanding is 0.94 Mil. Palisade Bio's float percentage of total shares outstanding is 98.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Palisade Bio's Insider Ownership is 14.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Palisade Bio's Institutional Ownership is 0.32%.

Palisade Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Palisade Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.93	/	0.94
	=	98.55%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio (Palisade Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

7NS:Germany

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Executives

Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley	officer: Chief Financial Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones	officer: Chief Medical Officer	70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae	officer: Chief Operating Officer	675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam	director, officer: Chief Executive Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson	officer: Chief Medical Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center	10 percent owner	2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei	director	P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter	director, officer: Executive Chairman	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma	director	14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142